IPP Bureau

Biological E. announces CDSCO recommendation of its infant’s vaccine
Biological E. announces CDSCO recommendation of its infant’s vaccine

By IPP Bureau - September 01, 2022

Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)

Merck India inaugurates R&D Excellence Centre in Bangalore
Merck India inaugurates R&D Excellence Centre in Bangalore

By IPP Bureau - September 01, 2022

The Centre aims at promoting innovation among the scientific community to improve healthcare solutions around the globe

Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA
Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA

By IPP Bureau - September 01, 2022

COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan

Cipla (EU) to acquire an additional 13.10% stake in Cipla (Jiangsu) Pharmaceutical
Cipla (EU) to acquire an additional 13.10% stake in Cipla (Jiangsu) Pharmaceutical

By IPP Bureau - August 31, 2022

Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.

Alembic Pharmaceuticals receives USFDA Final Approval for Chlorthalidone Tablets
Alembic Pharmaceuticals receives USFDA Final Approval for Chlorthalidone Tablets

By IPP Bureau - August 31, 2022

Chlorthalidone Tablets USP, 25 mg and 50 mg, have an estimated market size of US $37 million for twelve months ending June, 2022 according to IQVIA

Granules India receives ANDA approval for Loperamide Hydrochloride and Simethicone Tablets
Granules India receives ANDA approval for Loperamide Hydrochloride and Simethicone Tablets

By IPP Bureau - August 31, 2022

Hikma launches seasonal allergic rhinitis nasal spray RYALTRIS in the US
Hikma launches seasonal allergic rhinitis nasal spray RYALTRIS in the US

By IPP Bureau - August 31, 2022

This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US

Zydus announces Phase IV DREAM-CKD trial of Desidustat in patients with CDK induced anemia
Zydus announces Phase IV DREAM-CKD trial of Desidustat in patients with CDK induced anemia

By IPP Bureau - August 31, 2022

The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.

Merck to present new data of oncology portfolio at ESMO 2022
Merck to present new data of oncology portfolio at ESMO 2022

By IPP Bureau - August 30, 2022

Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)

Thermo Fisher Scientific present new innovations to improve biopharmaceutical and proteomics workflows
Thermo Fisher Scientific present new innovations to improve biopharmaceutical and proteomics workflows

By IPP Bureau - August 30, 2022

New mass spectrometry instrument and consumables launch during IMSC 2022

KIMS Hospitals to acquire majority stake in Kingsway Hospitals, Nagpur
KIMS Hospitals to acquire majority stake in Kingsway Hospitals, Nagpur

By IPP Bureau - August 30, 2022

The existing hospital premises has the scope to further scale up the bed capacity as and when required in the future with minimal Capex.

Dr. Mansukh Mandaviya and Bhagwanth Khuba to grace Silver Jubilee function of NPPA
Dr. Mansukh Mandaviya and Bhagwanth Khuba to grace Silver Jubilee function of NPPA

By IPP Bureau - August 29, 2022

To mark the occasion, Integrated Pharmaceutical Database Management System 2.0 (IPDMS 2.0), an integrated responsive cloud-based application developed by NPPA with technical support from C-DAC will be launched

Ayush Minister unveils “Science Behind Suryanamaskar” book
Ayush Minister unveils “Science Behind Suryanamaskar” book

By IPP Bureau - August 29, 2022

The book “Science behind Suryanamaskar” has been compiled by the AIIA’s Department of Swasthavritta and Yoga.

Lupin receives tentative approval from USFDA for Dasatinib Tablets
Lupin receives tentative approval from USFDA for Dasatinib Tablets

By IPP Bureau - August 29, 2022

Dasatinib Tablets (RLD Sprycel) had estimated annual sales of USD 1569 million in the U.S. (IQVIA MAT June 2022).

Eiko Lifesciences enters into MOU with Delicare Lifesciences
Eiko Lifesciences enters into MOU with Delicare Lifesciences

By IPP Bureau - August 29, 2022

The MOU provides for assistance in the form of efficient working Capital Management, development and commercialisation of new products, logistic supply chain management support etc.

Latest Stories

Interviews

Packaging